Related Experiment Video
Updated: Jul 13, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Crosstalk between Aldosterone and Glycation through Rac-1 Induces Diabetic Nephropathy
Mayura Apte1, Mohd Shahnawaz Khan2, Nilima Bangar1
1Symbiosis School of Biological Sciences, Symbiosis International (Deemed University) (SIU), Lavale, Pune, Maharashtra State 412115, India.
Abstract:
Background: Advanced glycation end products (AGEs) interaction with its receptor (RAGE) and aldosterone (Aldo) through the mineralocorticoid receptor (MR) activates Rac-1 and NF-κB independently in diabetic nephropathy (DN). However, the crosstalk of Aldo with AGEs-RAGE is still unresolved. Our study examined the impact of the AGEs-Aldo complex on renal cells and its effect on the RAGE-MR interaction. Methods and results: Glycation of human serum albumin (HSA) (40 mg/mL) with methylglyoxal (10 mM) in the presence of Aldo (100 nM) and aminoguanidine (AG) (100 nM) was performed. Glycation markers such as fructosamine and carbonyl groups and fluorescence of AGEs, pentosidine, and tryptophan followed by protein modification were measured. Renal (HEK-293T) cells were treated with the glycated HSA-Aldo (200 μg/mL) along with FPS-ZM1 and spironolactone antagonists for RAGE and Aldo, respectively, for 24 h. Glycation markers and esRAGE levels were measured. Protein and mRNA levels of RAGE, MR, Rac-1, and NF-κB were estimated. Glycation markers were enhanced with Aldo when albumin was only 14-16% glycated. AGEs-Aldo complex upregulated RAGE, MR, Rac-1 and NF-κB expressions. However, FPS-ZM1 action might have activated the RAGE-independent pathway, further elevating MR, Rac-1, and NF-κB levels. Conclusion: Our study concluded that the presence of Aldo has a significant impact on glycation. In the presence of AGEs-Aldo, RAGE-MR crosstalk exerts inflammatory responses through Rac-1 in DN. Insights into this molecular interplay are crucial for developing novel therapeutic strategies to alleviate DN in the future.
Insights
Aldosterone (Aldo) enhances glycation, and the complex of advanced glycation end products (AGEs) with Aldo promotes inflammation in diabetic nephropathy (DN) via RAGE-MR crosstalk and Rac-1 activation.
Area of Science:
- Biochemistry
- Molecular Biology
- Nephrology
Background:
- Advanced glycation end products (AGEs) and aldosterone (Aldo) activate Rac-1 and NF-κB independently in diabetic nephropathy (DN).
- The interaction between AGEs receptor (RAGE) and mineralocorticoid receptor (MR) in response to Aldo is not fully understood.
- This study investigates the crosstalk between AGEs-RAGE and Aldo-MR signaling pathways in renal cells.
Purpose of the Study:
- To examine the impact of the AGEs-Aldo complex on renal cells.
- To investigate the effect of the AGEs-Aldo complex on RAGE-MR interaction.
- To elucidate the molecular mechanisms underlying inflammation in diabetic nephropathy.
Main Methods:
- Human serum albumin (HSA) was glycated in the presence of Aldo and aminoguanidine (AG).
- Glycation markers, AGEs, and pentosidine levels were measured.
- Renal cells were treated with glycated HSA-Aldo and antagonists for RAGE and Aldo, followed by analysis of RAGE, MR, Rac-1, and NF-κB expression.
Main Results:
- Aldo significantly enhanced glycation markers, even with low HSA glycation.
- The AGEs-Aldo complex upregulated the expression of RAGE, MR, Rac-1, and NF-κB.
- RAGE antagonist treatment suggested a potential RAGE-independent pathway activation.
Conclusions:
- Aldosterone plays a critical role in promoting glycation.
- AGEs-Aldo complex-induced RAGE-MR crosstalk triggers inflammatory responses via Rac-1 in DN.
- Understanding this interplay is vital for developing targeted therapies for diabetic nephropathy.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hormonal Regulation

